Therapy resistance mechanisms in Ewing's sarcoma family tumors (Q38182423)

30 August 2017

Therapy resistance mechanisms in Ewing's sarcoma family tumors (English)

1 reference

30 August 2017

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24469502%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

author name string

Hamid Zia

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24469502%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Lars Wagner

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24469502%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

publication date

29 January 2014

1 reference

Cancer Chemotherapy and Pharmacology

30 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24469502%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

volume

73

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24469502%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24469502%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

page(s)

657-663

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24469502%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00280-014-2392-1

2 June 2020

exact match

0 references

cites work

Molecular pathogenesis and targeted therapeutics in Ewing sarcoma/primitive neuroectodermal tumours

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2392-1

Advances in Ewing's sarcoma research: where are we now and what lies ahead?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2392-1

The Ewing family of tumors. Ewing's sarcoma and primitive neuroectodermal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2392-1

Prognostic factors and clinical outcome of patients with Ewing's sarcoma family of tumors in adults: multicentric study of the Anatolian Society of Medical Oncology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2392-1

Critical signaling pathways in bone sarcoma: candidates for therapeutic interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2392-1

Past failures and future possibilities in Ewing's sarcoma:Experimental and preliminary clinical results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2392-1

Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2392-1

Treatment strategies for metastatic Ewing's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2392-1

Do stem-like cells play a role in drug resistance of sarcomas?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2392-1

Targeting CSCs within the tumor microenvironment for cancer therapy: a potential role of mesenchymal stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2392-1

Sarcoma stem cells: do we know what we are looking for?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2392-1

Salient features of mesenchymal stem cells-implications for Ewing sarcoma modeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2392-1

Mesenchymal Stem Cells and the Origin of Ewing's Sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2392-1

CD133 expression in chemo-resistant Ewing sarcoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2392-1

Potential for therapeutic targeting of tumor stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2392-1

Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2392-1

MicroRNAs in Ewing Sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2392-1

miR-125b develops chemoresistance in Ewing sarcoma/primitive neuroectodermal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2392-1

miR-34a predicts survival of Ewing's sarcoma patients and directly influences cell chemo-sensitivity and malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2392-1

EWS/FLI1 regulates EYA3 in Ewing sarcoma via modulation of miRNA-708, resulting in increased cell survival and chemoresistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2392-1

Survivin, a target to modulate the radiosensitivity of Ewing's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2392-1

Immunohistochemical detection of P-glycoprotein in Ewing's sarcoma and peripheral primitive neuroectodermal tumors before and after chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2392-1

Involvement of P-glycoprotein and MRP1 in resistance to cyclic tetrapeptide subfamily of histone deacetylase inhibitors in the drug-resistant osteosarcoma and Ewing's sarcoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2392-1

The role of aldehyde dehydrogenase (ALDH) in cancer drug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2392-1

High ALDH activity identifies chemotherapy-resistant Ewing's sarcoma stem cells that retain sensitivity to EWS-FLI1 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2392-1

The role of glutathione-S-transferase in anti-cancer drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2392-1

Targeting glutathione-S transferase enzymes in musculoskeletal sarcomas: a promising therapeutic strategy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2392-1

Cytochrome P450 CYP3A4/5 expression as a biomarker of outcome in osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2392-1

Biomarkers in Ewing Sarcoma: The Promise and Challenge of Personalized Medicine. A Report from the Children's Oncology Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2392-1

The clinical use of biomarkers as prognostic factors in Ewing sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2392-1

The insulin-like growth factor system and sarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2392-1

Targeting the Insulin-Like Growth Factor 1 Receptor in Ewing's Sarcoma: Reality and Expectations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2392-1

Development of IGF-IR Inhibitors in Pediatric Sarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2392-1

Biological rationale and current clinical experience with anti-insulin-like growth factor 1 receptor monoclonal antibodies in treating sarcoma: twenty years from the bench to the bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2392-1

Identification of common and distinctive mechanisms of resistance to different anti-IGF-IR agents in Ewing's sarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2392-1

Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2392-1

Expression of therapeutic targets in Ewing sarcoma family tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2392-1

MAPK/ERK Signaling in Osteosarcomas, Ewing Sarcomas and Chondrosarcomas: Therapeutic Implications and Future Directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2392-1

Type 1 insulin-like growth factor receptor targeted therapies in pediatric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2392-1

ERBB4 confers metastatic capacity in Ewing sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2392-1

The human phosphotyrosine signaling network: evolution and hotspots of hijacking in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2392-1

Tumor heterogeneity: mechanisms and bases for a reliable application of molecular marker design

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2392-1

Cancer heterogeneity: implications for targeted therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2392-1

The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2392-1

Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2392-1

How to escape the cancer attractor: rationale and limitations of multi-target drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2392-1

Cancer attractors: a systems view of tumors from a gene network dynamics and developmental perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2392-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2392-1